Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05810597 · ClinicalTrials.gov registry record · Phase 1
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT05810597 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 65 participants.
The verdict
NCT05810597, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of tirzepatide and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 14 weeks, including screening.
Interventions
- DRUG Tirzepatide
- DEVICE Single Dose Pen
- DEVICE Multi-use Prefilled Pen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2023-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05810597
The ClinicalTrials.gov registry entry for NCT05810597 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tirzepatide is the first listed.
NCT05810597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05810597 about?
NCT05810597 is a clinical study titled "A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices". The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of tirzepatide and information abou...
What is the current status of trial NCT05810597?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2023-04-03. Estimated completion is 2023-07-17.
What interventions are being tested in trial NCT05810597?
The interventions under investigation include: Tirzepatide (DRUG), Single Dose Pen (DEVICE), Multi-use Prefilled Pen (DEVICE).
Who is sponsoring clinical trial NCT05810597?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.